VOR trial update highlights late-stage progress for Telitacicept
Telitacicept is advancing in late-stage trials for myasthenia gravis and Sjögren's disease, with differentiation tied to its dual BAFF-APRIL mechanism and robust safety data from China.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.